Editas Medicine (NASDAQ:EDIT) executives outlined the company’s in vivo CRISPR gene-editing strategy and near-term clinical plans during a recent discussion featuring President and CEO Gilmore O’Neill ...

Rapid advancements in CRISPR and next-generation gene editing technologies, combined with a strong clinical pipeline ...

Add Yahoo as a preferred source to see more of our stories on Google. Stanford researchers have developed CRISPR-GPT, an AI-powered copilot that guides gene-editing experiments. (CREDIT: Shutterstock) ...

CRISPR gene editing has transitioned from a laboratory curiosity to a cornerstone of modern biotechnology, revolutionizing our approach to genetic diseases, including Charcot-Marie-Tooth (CMT) disease ...

Stanford Medicine researchers have developed an artificial intelligence tool to help scientists better plan gene-editing experiments. The technology, CRISPR-GPT, acts as a gene-editing “copilot” ...

Stanford Medicine researchers have developed an artificial intelligence tool to help scientists better plan gene-editing experiments. The technology, CRISPR-GPT, acts as a gene-editing "copilot" ...

Tools like CRISPR-Cas9 are creating new opportunities for innovation in St. Louis, as well as risks around IP protection and regulation.

One year after receiving CRISPR gene editing therapy at CHOP, a Delaware County baby is thriving, and doctors want to expand ...

Cathie Wood’s ARK Invest added to several beaten-down technology and biotech names while trimming positions elsewhere. The ...

CRISPR technology, enabling precise DNA editing, drives gene-editing stocks with major disease treatment potential. Leading companies like Intellia Therapeutics, CRISPR Therapeutics, and Beam focus on ...